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Abstract 
Rationale: Gastric cancer (GC) is a solid tumor that contains subpopulations of cancer stem cells (CSCs), 
which are considered drivers of tumor initiation and metastasis; responsible for therapeutic resistance; and 
promoters of tumor relapse. The balance between symmetric and asymmetric division is crucial for stem cell 
maintenance. The objective of this study is to evaluate the role of MAD2, a key protein for proper mitotic 
checkpoint activity, in the tumorigenesis of GC. 
Methods: Gastric cancer stem cells (GCSCs) were obtained from MKN45, SNU638 and ST2957 cell lines. 
Pluripotency and stemness markers were evaluated by RT-qPCR and autofluorescence and membrane markers 
by flow cytometry. Relevant signal transduction pathways were studied by WB. We analysed cell cycle 
progression, migration and invasion after modulation of MAD2 activity or protein expression levels in these in 
vitro models. In vivo assays were performed in a nude mouse subcutaneous xenograft model. 
Results: We found that NANOG, CXCR4 and autofluorescence are common and consistent markers for the 
GCSCs analysed, with other markers showing more variability. The three main signalling pathways 
(Wnt/β-catenin; Hedgehog and Notch) were activated in GCSCs. Downregulation of MAD2 in MKN45CSCs 
decreased the expression of markers CXCR4, CD133, CD90, LGR5 and VIM, without affecting cell cycle profile 
or therapy resistance. Moreover, migration, invasion and tumor growth were clearly reduced, and accordingly, 
we found that metalloprotease expression decreased. These results were accompanied by a reduction in the 
levels of transcription factors related with epithelial-to-mesenchymal transition. 
Conclusions: We can conclude that MAD2 is important for GCSCs stemness and its downregulation in 
MKN45CSCs plays a central role in GC tumorigenesis, likely through CXCR4-SNAI2-MMP1. Thus, its potential 
use in the clinical setting should be studied as its functions appear to extend beyond mitosis. 
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Introduction 
Gastric cancer (GC) is the fifth most frequent 
neoplasm and the third deadliest cancer in the world 
(GLOBOCAN 2018). Treatment strategies for 
localized tumors include surgery followed by chemo- 
or radiotherapy. Despite the development and 
identification in recent years of novel anticancer 
agents and treatment alternatives, a high percentage 
of GC patients eventually relapse, resulting in an 
overall 5 year survival rate of only 20-30% [1]. In GC, 
drug resistance, metastasis and recurrence may be 
largely due to the existence of GC stem-like cells 
(GCSCs) within the tumor [2, 3]. CSCs possess the 
ability to self-renew and differentiate into multiple 









contributors in tumor aggressiveness, metastasis, 
chemotherapy resistance and relapse [4]. CSCs 
express specific markers, which depend on the type of 
tumor and the specific subpopulation of cells from 
which they originate. Several markers have been 
described for GCSCs, including CD44, CD90, CD133, 
EpCAM, ALDH1, CXCR4 and LGR5 [5]. The level of 
expression of these markers depends on their origin 
and also on the properties of the primary tumor, 
which makes it mandatory to perform specific studies 
to thoroughly characterize the GCSC subpopulation 
within each tumor or cell line [6]. In general, CSCs 
show activation of the major signaling pathways: 
Hedgehog, Wnt/β-catenin and Notch, which are 
implicated in the regulation of epithelial-to- 
mesenchymal plasticity (EMP), one of the main 
characteristics leading to the described aggressiveness 
of these cells [7]. 
A CSC can follow one of two paths: 
differentiation or self-renewal. If it divides 
asymmetrically, the result will be one CSC and one 
specialized differentiated cell. However, the alternate 
self-renewal path results in two identical CSCs. Thus, 
like stem cells, CSCs undergo hierarchical branched 
division [8]. During this process, cell cycle 
checkpoints play a key role, especially the mitotic 
checkpoint. The spindle assembly checkpoint (SAC) is 
a complex of proteins that includes MAD1, MAD2, 
BUB1, BUBR1, BUB3, and MPS1, which controls 
proper spindle formation and orientation ensuring 
that every chromosome kinetochore is correctly 
attached to centrosome microtubules. MAD2 
participates in the mitotic checkpoint complex (MCC), 
which can bind and inhibit the anaphase promoting 
complex (APC/C). When all kinetochores have 
correctly attached, the SAC turns off and the MCC 
disassembles, thus freeing CDC20 for APC/C 
activation. The APC/C-CDC20 complex targets 
securine and cyclin B1 for degradation resulting in 
sister chromatid separation and mitosis exit, 
respectively. The cleavage plane also establishes the 
partition of cellular contents, including cell-fate 
determinants. This is critical for stem cell self-renewal 
and differentiation [9, 10]. The role of several 
checkpoint proteins has been studied in cancer, like 
MAD2 and BUBR1, and the levels of these proteins 
have been associated with tumorigenesis or clinical 
prognosis [11-13]. 
GC presents a large degree of inter- and 
intratumoral heterogeneity, which can have both 
genetic and non-genetic bases. Chromosomal 
instability (CIN) can be responsible for high 
intratumoral genetic heterogeneity. The non-genetic 
heterogeneity (i.e epigenetics and microRNAs) is the 
heterogeneity that arises due to EMP, to the ability of 
cells to maintain their plasticity and transit between 
epithelial-mesenchymal transition (EMT) and 
mesenchymal-epithelial transition (MET) [14]. These 
cell transitions allow cells to migrate away from the 
primary tumor and thus invade secondary sites. EMT 
is a transcriptionally-mediated process and is 
associated with cell morphological changes that result 
in enhanced cellular migration and invasion, the latter 
of which is facilitated by degradation and remodeling 
of the extracellular matrix, the sum of which 
ultimately leads to the successful colonization of 
cancer cells at secondary sites [6]. In this process of 
matrix remodeling, matrix metalloproteinases 
(MMPs) play an essential role degrading the basement 
membrane and extracellular matrix. There is evidence 
that some MMPs are implicated in EMT induction, 
such as MMP3, which directly regulates E-Cadherin 
and also participates in the regulation of the Wnt 
pathway [15]. Levels of MMPs, such as MMP1, 2 and 
9, have been found to be increased in GC, and their 
overexpression has been shown to be associated with 
tumor invasion and metastasis [16]. EMT is tightly 
correlated with the activation of EMT transcription 
factors, such as ZEB1, SNAI1 (SNAIL), SNAI2 (SLUG) 
and TWIST [17]. However, during EMT progression, 
cells can exhibit a hybrid epithelial/mesenchymal 
(E/M) phenotype, in which cells will co-express 
epithelial and mesenchymal markers. In fact, stemness 
also associates with cells that adopt the hybrid E/M 
state [18], inducing tumor cells to develop stem cell 
characteristics, which promote cells to invade 
surrounding tissues and contribute to therapeutic 
resistance [19]. 
We previously described that MAD2 is 
overexpressed in several GC cell lines [13]; however, 
the specific role of MAD2 in tumorigenesis remains 
controversial. Since the majority of recent work 
suggest that models based on CSCs are biologically 
more relevant, our aim was to analyze the role of 
MAD2 in GCSCs. We show that MAD2 is involved in 
the regulation of different stem-associated properties 
of the MKN45 cell line, suggesting an array of new 
potential functions for this protein, all of which we 
aim to study here in detail to elucidate possible 
applications for the clinical setting. 
Materials and Methods 
Cell lines and chemicals 
The human GC adenocarcinoma cell lines 
MKN45, SNU1, and SNU638 (poorly differentiated; 
DSMZ: Deutsche Sammlung von Mikroorganismen 
und Zellkulturen GmbH), ST2957 (lymph node 
metastases), and AGS (primary tumor; ATCC/LGC 
Standards, Spain) were cultured in RPMI 1640 





(Sigma), DMEM (Gibco) and HAM’s F-12 + AA’s 
(Gibco), respectively, according to the specifications 
of the manufacturer´s datasheet and supplemented 
with 10% FBS, 2 mM L-Glutamine, Fungizone 1× and 
0.07% Gentamicin. Cultures were maintained at 37 ºC, 
5% CO2 and 95% humidity. Mycoplasma 
contamination is routinely tested in our laboratory. 
Cisplatin (CDDP) was kindly donated from 
Ferrer FARMA, Bleomycin (BLM) acquired from 
Calbiochem and Paclitaxel (PXL) and Puromycin 
purchased from Sigma-Aldrich. MTS was acquired 
from Promega and M2i-1 inhibitor was purchased 
from Cayman Chemical. 
Tumor sphere assay 
GC cells were cultured in DMEM/F12 
(Invitrogen) supplemented with B-27 (10889038, 
Gibco), 2 mM L-Glutamine, Fungizone 1×, 0.07% 
Gentamicin, 20 ng/mL EGF and 20 ng/mL bFGF. 
These cells were seeded in ultra-low-attachment 
6-well plates (3×103 cells/3 mL in each well) and 
maintained in a humidified incubator (5% CO2 at 37 
°C). Fresh medium was added to the culture every 
few days, and the culture was analyzed daily for 
tumor sphere formation (up to the seventh day). 
Representative images were captured using a Nikon 
Eclipse TS100 microscope. For these experiments, cells 
were grown in ULA Flasks or plates for 5-6 days, and 
for serial passaging, spheres were harvested using a 
40 µm cell strainer, dissociated to single cells with 
trypsin, and re-grown in the same conditions for 5-6 
days (in general, secondary spheres were used for all 
experiments). 
RT-qPCR 
Total cellular RNA was extracted using 
Tri-Reagent (Life Technologies), following the 
manufacturer’s instructions. One microgram of total 
RNA was primed with poly-T and cDNA synthesized 
with M-MLV reverse transcriptase following the 
manufacturer’s instructions (Promega). Target genes 
were amplified using the SYBR Green polymerase 
chain reaction assay, using the specific primer sets 
listed in the table below: 
 
Table 1. Primer sequences 
Primer Sequence 
CDH1 (E-cadherin) F: CCATTCTGGGGATTCTTGGAGG 
R: GCAGCTGGCTCAAGTCAAAGTC 
VIM (Vimentin) F: GCTCAATGTTAAGATGGCCC 
R: CAGAGGGAGTGAATCCAG 
SOX2 F: GCACATGAACGGCTGGGAGC 
R: GCGAGTAGGACATGCTGTAGG 
NANOG F: TCTCTCCTCTTCCTTCCTCC 
R: GGAAGAGTAAAGGCTGGGG 
OCT3/4 F: GCAACCTGGAGAATTTGTTCC 
R: GACCCAGCAGCCTCAAAATC 
LGR5 F: CCTCTGCTGGCTTTTAGGTG 
Primer Sequence 
R: TGAAAGGCCTGAAAACTGCT 
LOXL2 F: GGAGAGGACATACAATACCAAAGTG 
R: CCATGGAGAATGGCCAGTAG 
MAD2L1 F: GCTTGTAACTACTGATCTTG 
R: GCAGATCAAATGAACAAGAA 
BUB1B F: TCGTGGCAATACAGCTTCAC 
R: GGTCAATAGCTCGGCTTCC 
MMP9 F: GAGTTCCCGGAGTGAGTTGA 
R: AAAGGTGAGAAGAGAGGGCC 
MMP2 F: GGGGTGAAAATGGAGGGAGA 
R: CCGACTCTTAAAGCTTCCGC 
MMP1 F: CTTGCACTGAGAAAGAAGACAAAGG 
R: ACACCCCAGAACAGCAGCA 
SNAI1 F: CTCCCTGTCAGATGAGGAC 
R: CCAGGCTGAGGTATTCCTTG 
SNAI2 F: GGGGAGAAGCCTTTTTCTTG 
R: TCCTCATGTTTGTGCAGGAG 
ZEB1 F: CCAGGTGTAAGCGCAGAAA 
R: CCACAATATGCAGTTTGTCTTCA 
TWIST F: AGGGCTCTCAGAAGAGGACC 
R: AAGGAAAAGAATAGCCGGCGT 
CDKN1A (p21) F: GCTGCAGGGGACAGCAGAG 
R: GCTTCCTCTTGGAGAAGATCAG 
IL6 F: GCCAGAGCTGTGCAGATGAG 
R: CAGTGGACAGGTTTCTGACC 
GAPDH F: GAGAGACCCTCACTGCTG 
R: GATGGTACATGACAAGGTGG 
 
IL-8 expression was measured (Hs00174103_m1) 
using a TaqMan® Universal PCR Master Mix 
(Applied Biosystems-Thermo Fisher, P/N 4304437, 
Foster City, CA), and GAPDH (Hs99999905_m1). 
Thermal cycling of the qPCR reaction was initiated 
with a denaturation step at 95 °C for 10 min, and 
consisted of 40 cycles (denaturation at 95 °C for 15 sec, 
annealing at 60 °C for 30 sec, and elongation at 75 ºC 
for 30 sec). PCR amplifications were carried out in a 
StepOne Real‐time PCR System (Applied Biosystems, 
4376357). Relative mRNA levels were calculated by 
the delta-Ct method (2-ΔΔCt), where each 1-Ct 
difference equals a 2 fold change in transcript 
abundance, using GAPDH as an endogenous 
reference. ΔΔCT represents the difference between the 
mean ΔCT value of the cells tested and the mean ΔCT 
value of the calibrator, both calculated for the same 
PCR run. 
Western Blotting 
Total protein extracts were obtained using the 
previously described lysis buffer [20]. Twenty μg of 
protein per sample were loaded in 8%, 10% or 15% 
SDS-PAGE polyacrylamide gels, and then transferred 
onto PVDF membranes, followed by immuno-
detection using appropriate antibodies. Antibodies 
against the following proteins were used: SOX2 
(sc-365823; 1:1000), NANOG (sc-293121; 1:1000), 
MAD2 (sc-28261; 1:1000), BUBR1 (sc-47744; 1:1000), 
Cyclin B1 (sc-166757; 1:1000) and β-ACTIN (sc-47778; 
1:1000) were purchased from Santa Cruz Biotech-
nology; GLI1 (#3538 1:1000), NOTCH1 (#3608; 
1:1000), Cyclin A2 (#4656; 1:1000), Cyclin D1 (#2926; 
1:1000), phospho-CDK1Tyr15 (#9111; 1:2000), CDK1 





(#9112; 1:1000) and phospho-Histone H3Ser10 (#3377; 
1:1000) were all purchased from Cell Signaling 
Technology; Antibody to β-catenin (610154; 1:1000) 
was acquired from BD Transduction Laboratories and 
finally, α-Tubulin (1:10,000) from Sigma. Secondary 
antibodies conjugated with horseradish peroxidase 
were purchased from BioRad, and chemi-
luminescence detection was performed using ECL 
(Santa Cruz Biotechnology). 
Flow cytometry 
Cells were analyzed with a 4-laser Attune NxT 
Acoustic Cytometer (Thermo Fisher Scientific). 
Samples were resuspended in FLOW buffer (1x PBS; 
3 mM EDTA (v/v); 3% FBS (v/v)), and the following 
fluorescently tagged antibodies were used to label 
cells for 30 minutes at 4°C: mouse monoclonal 
anti-human CXCR4-PE (5:50, REA649; 130-117-354, 
Miltenyi Biotec), mouse monoclonal anti-human 
CD44-PE (1:50; 555479, BD Pharmingen), mouse 
monoclonal anti-human CD90-APC (2.5:50, 5E10; 
A15726, Life Technologies) and mouse monoclonal 
anti-human CD133-PEVio770 (1:50, AC133; 130-113- 
110, Miltenyi Biotec). Autofluorescent cells were 
excited with blue laser 488 nm and selected as the 
intersection with the filters 530/40 and 580/30 as 
previously described [21]. DAPI was used to identify 
and exclude dead cells, and data were then analyzed 
using FlowJo v9.3 software (Tree Star Inc., Ashland, 
OR). 
AldeRed ALDH detection assay 
The AldeRed with 588-A ALDH Detection Assay 
(SCR150, Millipore) was used, following the 
manufacturer's instructions. Briefly, 2×105 cells were 
resuspended in AldeRed assay buffer containing the 
AldeRed 588-A substrate. The cell suspension was 
split into two fractions, one half of which served as a 
control, and was transferred to a new tube containing 
the specific ALDH1 inhibitor diethylamino- 
benzaldehyde (DEAB). Cells were then incubated for 
45 min at 37°C in complete darkness. Next, cells were 
centrifuged (300 g, 5 min), their supernatants 
discarded, and cell pellets resuspended in 500 μL of 
cold AldeRed assay buffer. Samples were stored on 
ice and darkness prior to flow cytometry analysis 
(4-laser Attune NxT Acoustic Cytometer; Thermo 
Fisher Scientific). DAPI was used to mark and exclude 
dead cells, and data was analyzed using FlowJo v9.3 
software (Tree Star Inc., Ashland, OR). 
Viral transduction of cells 
Viral particles were generated according to the 
manufacturer's instructions using GIPZ Lentiviral 
shRNA for MAD2L1 (Thermo Scientific Open 
Biosystems). Briefly, 4.5×106 HEK293 cells/plate in 
DMEM medium were transfected using lipofectamine 
2000 (Invitrogen) with 15 μg of shMAD2L1 or 
non-silencing shRNA, 7 μg of envelope plasmid 
(VSV-G) and 7 μg of Helper plasmid (pCD/NL-BH). 
Supernatants were recovered 48 h and 72 h after 
transfection, filtered and frozen in small aliquots at 
-80°C until use. Infections were performed using 
5×105 of indicated cells per well in a 6-well plate with 
1 mL of viral containing supernatants. Cells were then 
examined microscopically 48 h later to verify the 
presence of GFP expression as an indicator of 
transduction efficiency. Cells were assayed 72 h later 
to evaluate potential reductions in gene expression by 
RT-qPCR (compared to non-silencing shRNA). 
Efficiency of secondary sphere formation assay 
MKN45, ST2957 and SNU638 CSC enriched 
sphere-derived cells were maintained in 
supplemented DMEM/F12 media and after 5-6 days, 
spheres were harvested and trypsinized to induce 
sphere dissociation, and single cells were seeded 
again in ultra-low-attachment 96-well plates for 
secondary sphere formation (1 cell per well for 
MKN45, 25 cells for ST2957 and 250 cells for SNU638). 
Fresh medium was added to the culture every few 
days, and after 10 days, spheres were counted and 
Sphere Forming Efficiency (SFE) was calculated as the 
number of spheres formed relative to the number of 
seeded cells, and expressed as % mean ± SD. For 
analysis of the SFE from 1-single cell, MKN45 cells 
were sorted in ultra-low-attachment 96-well plates 
using the FACSVantage SE Flow Cytometer (Becton 
Dickinson). For the experiments with the MAD2 
inhibitor, M2i-1, cells were seeded as previously 
described in the presence of 25 µM M2i-1, which was 
added again on the fifth day. 
BrdU Incorporation Analysis 
MKN45 and ST2957 CSC enriched sphere- 
derived cells were seeded in ultra-low-attachment 
6-well plates (1.5×105 cells/3 mL per well) and 
allowed to form secondary spheres for 5 days, after 
which we added 10 µM BrdU for 1 hour. After BrdU 
incubation, cells were washed with PBS, trypsinized, 
fixed with 70% cold EtOH and stored at -20°C for at 
least 2 hours. To stain cells with fluorescence-labeled 
antibody, cells were washed once with PBS and 
permeabilized with 3 N HCl for 20 min at room 
temperature. Then, cells were washed with PBS three 
times and incubated with blocking solution (1% BSA - 
0.05% Tween 20 - PBS) for 15 min at room 
temperature. Next, we added the FITC mouse 
anti-BrdU antibody (1:50, 556028 BD Pharmingen) 
and incubated samples for 1 h at 37°C in the darkness. 
Later, PI (50 µg/ml) and RNAse (10 µg/ml) were 





added, without removing the previous solution, and 
samples were incubated overnight at 4°C in darkness. 
Cell DNA content and BrdU incorporation were 
evaluated using a FACSCANTOII Flow Cytometer 
(Becton Dickinson) and results were analyzed using 
BD FACSDiVa Software. 
Cell cycle profile analysis 
MKN45 2nd generation CSC enriched sphere- 
derived cells without/with MAD2L1 downregulation 
were trypsinized, fixed with 70% cold EtOH and 
stored at 4°C overnight. Cells were incubated with PI 
(50 µg/mL) and RNAse (10 µg/mL) for 30 min and 
DNA content were evaluated using a FACSCANTOII 
Flow Cytometer (Becton Dickinson). Results were 
analyzed using BD FACSDiVa Software. 
Cell viability 
Viability was determined using a MTS 
(Promega) staining method. For this, 5×103 adherent 
cells were seeded per well in 96 multi-well plates and 
the following day they were treated with various 
amounts of CDDP (0-10 µg/mL), BLM (0-10 µg/mL) 
and PXL (0-0.5 µM). CSC enriched sphere-derived 
cells (1×103 cells for MKN45 and 5×103 cells for 
SNU638 per well) were seeded in ultra-low- 
attachment 96-well plates. Four days later, secondary 
spheres were treated the same way as adherent cells 
were. 72 h post treatment initiation, 10 μL/well MTS 
solution was added to each well, and after incubation 
in the darkness for 1-4 h (37°C, 5% CO2), absorbance 
was recorded at 490 nm. 
Cell migration and invasion assay 
Migration and invasion assays were performed 
in a cell culture insert with a transparent PET 
Membrane (6.5 mm diameter, 8.0 μm pore size) 
(transwell migration and invasion assays) (Falcon, 
Corning Inc., Corning, NY, USA), coated with 6 μg 
growth factor reduced Matrigel (BD Biosciences, 
Bedford, MA, USA) for invasion assay. 2nd generation 
CSC enriched sphere-derived cells (1.5×105) were 
seeded in the upper chamber, and 20% serum-free 
conditioned medium from M2-differentiated human 
macrophages, generated as described in [22], was 
used as a chemoattractant and placed in the bottom 
chamber. Cells were allowed to migrate or invade for 
48 h at 37°C with 5% CO2. Then, non-migrating and 
non-invading cells were removed using a cotton 
swab, and the filters were stained with Diff Quik 
(Dade Behring, Newark, DE, USA). Migratory and 
invasive cells were counted in 50 fields of maximum 
migration or invasion under a light microscope at 40× 
magnification. Representative images were captured 
using an Axiophot Zeiss microscope. 
Gelatin Zymography 
MKN45 CSC enriched sphere-derived cells were 
seeded in ultra-low-attachment 6-well plates (1.5×105 
cells/3 mL in each well) and after five days forming 
secondary spheres, they were washed with PBS and 
resuspended in free DMEM/F-12 medium for 48 h. 
Conditioned medium was harvested and centrifuged 
at 2000 rpm for 5 min. Then, the conditioned medium 
was concentrated using centrifugal filter devices 
(Amicon Ultra-4; Millipore) and stored at -80°C. 
Media containing 20 µg of total proteins was 
resuspended in non-reducing sample buffer (62.5 mM 
Tris-HCl pH 6.8, 1% SDS, 12.5% glycerol, 0.004% 
bromophenol blue), warmed at 37°C for 15 min and 
run in a 7.5% polyacrylamide gel containing 0.25% 
gelatin. After electrophoresis, the gel was washed 
twice (30 min each) with washing buffer (50 mM Tris–
HCl pH 7.5, 2.5% Triton X-100, 5 mM CaCl2 and 1 µM 
ZnCl2) with gentle agitation at RT. Next, the gel was 
washed for 10 min with incubation buffer (50 mM 
Tris–HCl pH 7.5, 1% Triton X-100, 5 mM CaCl2 and 1 
µM ZnCl2) at RT and then incubated with new 
incubation buffer at 37°C for 48 h with gentle 
agitation. After incubation, the gel was stained with 
staining solution (0.5% Coomassie Brilliant Blue R-250 
(161-0400 Bio-Rad Laboratories), 40% methanol, 10% 
acetic acid) for 30 min - 1 h and destained with 
destaining solution (40% methanol, 10% acetic acid) 
until gelatinolytic bands appeared as a clear white 
zone against a blue background. The intensity of the 
gelatinolytic bands was quantified using ImageJ 
software. 
Tumor xenograft model 
MKN45 cells were trypsinized and 5×103 cells 
were resuspended in 50 µL medium with 40% 
Matrigel (Corning), and then subcutaneously 
injected into the flanks of female 5-week-old nude 
mice (Janvier Labs). To analyze the effect of the MAD2 
inhibitor M2i-1, we added 25 µM to the cell 
preparation before injecting into mice. Tumor growth 
and volumes were monitored every few days for up 
to 4 weeks with a caliper. Tumor volume (mm3) was 
computed using the formula: 0.5 × D12 × D2, where 
D1 and D2 are the width or the largest diameter and 
the length or the smallest diameter of a given tumor, 
respectively. After sacrifice by cervical dislocation, 
tumor mass was resected and trimmed; one fragment 
was embedded in OCT and frozen, and the others 
were directly frozen for protein and mRNA extraction 
and cDNA synthesis (as previously described, with an 
initial step of homogenization). OCT-embedded 
tumors were cut through the maximum diameter 
section plane and 5 µm-thick sections were obtained 
using a Leica Cryostat 1950 for H&E staining. Pictures 





of each slide were taken with a Nikon Eclipse 90i 
microscope and ImageJ software was used to stitch all 
microscopic fields together so as to make up the 
complete section. The viable tumor surface was 
calculated by drawing the viable areas using ImageJ 
software, which are distinguishable from necrotic 
areas. All animal experiments were conducted in 
accordance with FELASA guidelines and approved 
protocols. Mice were housed according to 
institutional guidelines and all experimental 
procedures were performed in compliance with the 
institutional guidelines for the welfare of 
experimental animals approved by the Universidad 
Autónoma de Madrid Ethics Committee (CEI 
60-1057-A068) and La Comunidad de Madrid (PROEX 
335/14) and in accordance with the guidelines for 
Ethical Conduct in the Care and Use of Animals as 
stated in The International Guiding Principles for 
Biomedical Research involving Animals, developed 
by the Council for International Organizations of 
Medical Sciences (CIOMS). 
Statistical analysis 
All data are presented as mean ± standard 
deviation (SD) after performing three independent 
experiments, unless otherwise stated. Statistical 
significance (at P < 0.05) was determined using one- 
way ANOVA, post hoc comparisons, Bonferroni’s 
test, or two-tailed Student's t-test, using GraphPad 
Prism version 5.0c (San Diego, California, USA). 
Results 
Isolation and characterization of gastric cancer 
stem cells (GCSCs) 
To evaluate the utility of GC cell lines as suitable 
models for CSC-based studies, GC cell lines (AGS, 
MKN45, SNU1, SNU638 and ST2957) were first plated 
in serum‐free medium under low‐adherent conditions 
to assess their capacity to form floating three‐
dimensional spheroids, enriched in cancer stem-like 
cells (CSCs), hereafter referred to as tumorspheres or 
gastrospheres. MKN45, ST2957 and SNU638 formed 
tumor spheres but not AGS or SNU1 cell lines (Figure 
1A and Figure S1A). To confirm the self‐renewing 
ability of spheroid forming cells, we enzymatically 
dissociated the primary spheres into single cells and 
re-cultured them to generate sub‐spheroid bodies 
again, and passaged them twice for at least 3 weeks in 
serum‐free CSC-specialized media under non- 
adherent conditions. Our results showed that 
spheroid body‐forming cells retain the ability to self‐
renew (Figure 1A). Interestingly, the sphere body- 
forming efficiency increased in MKN45 and SNU638 
cell lines in 2nd generation, but the maximum CSC 
enrichment was achieved in ST2957 in the first 
generation (Figure 1A). Moreover, to study the 
differentiation of GCSCs we disaggregated the 
spheres and cultivated individual cells in serum‐
containing medium under adherent conditions. Five 
days after seeding, we observed obvious phenotypical 
changes in our cells, which now showed an adherent 
morphology (Figure S1B). Finally, we evaluated the 
mesenchymal state of these CSC-enriched spheres by 
measuring the expression of 2 EMT-associated genes. 
This analysis revealed an increase of the expression of 
E-cadherin (CDH1), the major signature gene for 
epithelial cells, in SNU638CSCs, and a reduction in the 
expression of the mesenchymal marker vimentin 
(VIM) in all cells, reaching significance for MKN45CSCs 
(Figure 1C). 
To more definitively determine the stem-like 
state of GCSCs, the expression of pluripotency and 
stemness markers in sphere-forming cells compared 
with adherent cells was analyzed. RT-qPCR analysis 
showed that NANOG was sharply up-regulated in all 
GCSC-enriched cultures studied by 2, 6.6 and 5.8 
fold-times in MKN45, ST2957 and SNU638, 
respectively. Furthermore, SOX2 mRNA levels 
increased in ST2957CSCs (4 fold-times) and SNU638CSCs 
(2.5 fold-times), while MKN45CSCs showed an increase 
in the expression of OCT3/4 (2.7 fold-times) (Figure 
2A). To verify our RT-qPCR results, we checked SOX2 
and NANOG protein levels in these cell lines, and our 
WB results corroborated the above mRNA data 
(Figure S2A). We also checked other CSC markers, 
such as LGR5, whose expression increased around 5 
times in MKN45CSCs. In addition, a clear and 
significant rise in the expression of the metastatic 
EMT-associated gene LOXL2 both in MKN45CSCs (11.3 
fold-times) and ST2957CSCs (3 fold-times) cell lines was 
observed (Figure 2A). 
Finally, the expression of CSC markers was 
assessed by flow cytometry. First, we explored 
autofluorescence, a recently described CSC marker 
[21], which is the result of riboflavin accumulation in 
ABCG2-coated intracellular vesicles. Compared to 
their adherent cell counterparts, we observed an 
increase in MKN45CSCs, ST2957CSCs and SNU638SCs 
autofluorescence by 8, 4.25 and 5.7, respectively. 
Moreover, we investigated the expression of the 
plasma membrane marker CXCR4 and observed an 
increase in the percentage of positive cells in MKN45, 
ST2957 and SNU638, by 1.8, 3.4 and 3.9 fold-times, 
respectively. CD90 was only expressed in ST2957CSCs 
and not in adherent cells and increased by 2.65 
fold-times in MKN45CSCs. CD133 was 3.45 times 
higher in MKN45CSCs and we did not appreciate any 
modification in the expression of CD44 (Figure 2B and 
Figure S2B). We also analyzed ALDH1 activity, a 





functional CSC marker, and observed that CSCs from 
MKN45 and ST2957 showed a significant and 
pronounced increase in ALDH1 activity (Figure 2C 
and Figure S2C). Finally, we analyzed three well 
known signaling pathways commonly activated in 
CSCs: Hedgehog, Notch and Wnt/β-catenin. WB 
analysis of one representative component of each 
pathway (GLI1, cleavage-NOTCH1 and β-CATENIN, 
respectively) showed that all of these pathways are 
activated in CSCs enriched from the three GC cell 
lines (Figure 2D). 
 
 
Figure 1. Isolation of CSCs from GC cell lines. (A) Sphere formation assay for MKN45, ST2957 and SNU638 GC cell lines. Cells were grown in ultra-low-attachment 
6-well plates with DMEM/F-12 medium (3000 cells per well) containing specific supplements. Images are representative of 1st generation spheres taken at day 7 (time 0) and 2nd 
generation spheres taken 1, 4 and 7 days after plating. Scale bar: 100 µm. (B) Sphere formation efficiency in GCSCs. 1st and 2nd generation CSC enriched sphere-derived cells 
were seeded as follow: 10 cells/well for MKN45 and ST2957 and 100 cells/well for SNU638, and spheres were counted 10 days later. Graphs show the percentage of the total 
number of spheres formed/total number of cells seeded (SFE: sphere formation efficiency). (C) RT-qPCR was performed to measure E-cadherin (CDH1) and Vimentin (VIM) 
mRNA relative levels on samples from the three GC cell lines and their CSCs at day 7. Each gene was normalized to GAPDH and data were calculated as relative to human 
fibroblasts (set as 1.0). Three independent experiments were performed with similar results in (B) and (C). Statistical significance was evaluated by a one-way ANOVA, followed 
by post hoc comparison (Bonferroni´s test, *P < 0.05; **P < 0.01). ADH: adherent cells. CSCs: enriched CSC cultures. 






Figure 2. Characterization of GCSCs. (A) Relative levels of mRNA transcripts for pluripotency and stemness markers. The relative expression levels of NANOG, SOX2, 
OCT3/4, LGR5 and LOXL2 mRNAs were quantified by RT-qPCR in MKN45, ST2957 and SNU638 cell lines cultured in adherence (ADH) or as spheres (CSCs). Each gene was 
normalized to GAPDH. Fold changes were calculated and compared to ADH (set as 1.0). At least three independent experiments were performed with similar results. (B) Flow 
cytometric analysis for CXCR4, CD44, CD90 and CD133 cell surface expression and autofluorescence (Fluo) in the 3 GC cell lines cultured in adherence (ADH) or as spheres 
(CSCs). The histograms summarize the percentage of CXCR4-, CD44-, CD90-, CD133- and autofluorescent-positive cells from three different experiments. Fold changes were 
calculated compared to ADH (set as 1.0). (C) ALDH activity profile. MKN45, ST2957 and SNU638 cell lines cultured in adherence (ADH) or as spheres (CSCs) and were 
counter-stained with AldeRed to determine the frequency of ALDH-positive cells by flow cytometry, in the presence or absence of the ALDH inhibitor (DEAB). ALDH activity 
is expressed as mean of the percentage of positive cells of 3 experiments. (D) Activation of signaling pathways in CSCs. Representative Western Blot analysis for GLI1, cleaved 
Notch1 and β-catenin in the 3 GC cell lines cultured in adherent and sphere conditions. Graphs show the fold change of protein levels compared to ADH expression obtained 
in three different experiments performed under the same conditions. Protein levels were normalized with α-tubulin. The statistical significance was evaluated with two-tailed 
Student's t-test (*P < 0.05; **P < 0.01; ***P < 0.001). 






Figure 3. SAC key protein MAD2 and BUBR1 levels in GCSCs. RT-qPCR (A) and WB (B) analysis for MAD2L1 (MAD2) and BUB1B (BUBR1) in the 3 GC cell lines 
cultured in adherence (ADH), as sphere (CSCs) or re-differentiated cells (DIF). Each gene was normalized to GAPDH. Protein levels were normalized with β-actin. Data are 
shown as expression relative to human fibroblasts (Fb). The experiments were repeated three times with similar results. Statistical significance was evaluated with one-way 
ANOVA, followed by post hoc comparisons (Bonferroni´s test, *P < 0.05; **P < 0.01; ***P < 0.001). 
 
Altogether, our data suggests that these GC cell 
lines contain a pool of heterogeneous cells which 
show characteristics of CSCs, although differences 
between cells lines exist, as would be expected. 
Nevertheless, the GCSCs from MKN45, ST2957 and 
SNU638 have the ability of self-renewal and express, 
as common CSC markers, NANOG, CXCR4 and 
autofluorescence. 
Mitotic checkpoint 
Mitosis plays important roles in balancing the 
stem cell and non-stem cell populations via regulation 
of symmetric division (i.e. self–renewal) and 
asymmetric division (i.e. differentiation, giving rise to 
progenitor cells). We asked if the mitotic checkpoint 
proteins MAD2 and BUBR1 also play a role in the 
tumorigenic process of GCSCs. To this end, we 
quantified MAD2L1 and BUB1B mRNA and protein 
levels in the GC cell lines cultured both in adherent 
conditions or as spheres, and also evaluated and 
compared levels to primary human non-tumoral 
fibroblasts as non-tumoral gastric cells are 
unavailable. Our results showed that while MAD2L1 
and BUB1B mRNA levels are upregulated in both 
adherent cells and 2nd generation GCSC-enriched 
spheres compared to fibroblasts, adherent 
differentiated cultures have higher expression of both 
transcripts versus GCSC-enriched spheres: 9.8 vs 5.2 
fold-times in MKN45, 11.6 vs 5.8 in ST2957 and 15.1 vs 
10.7 in SNU638 for MAD2L1, and 7.2 vs 4.9 fold-times 
in MKN45, 5.9 vs 3.5 in ST2957 and 6.9 vs 4.5 in 
SNU638 for BUB1B (Figure 3A). In order to test if this 
overexpression was acquired during the 
differentiation process, we re-seeded 2nd generation 
GCSCs under adherent conditions (DIF) (as described 
for Figure 1B) and quantified the mRNA levels of 
these key mitotic proteins. Our results showed that 
re-differentiated cells upregulated MAD2L1 and 
BUB1B almost to the same levels as adherent cells (i.e. 
7.6, 9.7 and 15 fold-times of MAD2L1 mRNA levels in 
MKN45, ST2957 and SNU638, respectively). We 
verified these data by WB analysis, and confirmed the 
same trend for MAD2 and BUBR1 (Figure 3B). The 
sum of these data suggests that GCSCs overexpress 
MAD2 and BUBR1, which further increases during 
differentiation (i.e. asymmetric division). 
MAD2L1 interference modulates stemness 
characteristics 
These results prompted us to study the role of 
MAD2 in gastric tumorigenesis taking into account 
the fundamental importance of this protein in 
modulating mitotic checkpoint and asymmetric 
division [23]. Towards this end, we chose to continue 





with MKN45CSCs as this poorly differentiated 
adenocarcinoma cell line showed the most consistent 
results at the level of CSC phenotypes (Figure 2). We 
used an shRNA targeting MAD2L1 (shM), and 
performed RT-qPCR analysis to study the effect of 
MAD2 downregulation on the expression of 
pluripotency and stemness markers in MKN45CSCs, as 
described above. First, we confirmed the efficiency of 
MAD2L1 interference in MKN45 CSC 2nd 
generation-enriched cultures (Figure 4A). Next, we 
analyzed the cell cycle of shM versus non-interference 
(WT) to determine the effect of MAD2 silencing on 
GCSC cell cycle progression. We observed that the 
distributions of cells in different phases of the cell 
cycle were not significantly different comparing WT 
vs shM MKN45CSCs (Figure S3A). Moreover, we 
analyzed BrdU incorporation, and observed a slightly 
higher incorporation of BrdU index after MAD2 
downregulation (1.5 fold-times) (Figure S3B). To 
further analyze the cell cycle, we studied proteins 
directly involved in cell cycle control. Our results 
showed no differences in cyclin levels (Cyclin D1, 
Cyclin A2, Cyclin B1) or Cdk-kinases (CDK1 and 
pCDK1Y15), and a slight increase in HistoneH3Ser10 
phosphorylation (Figure S3C). Thus, we concluded 
that MAD2 silencing has a marginal effect on 
MKN45CSCs cell cycle progression. 
At the level of gene expression; however, we 
observed significant but variable changes in marker 
expression after MAD2L1 downregulation. Except for 
NANOG, pluripotency-associated genes were 
unaffected in shM versus WT MKN45CSCs. LGR5, also 
significantly decreased in shM versus WT. At the level 
of EMT- and metastasis-associated genes, no changes 
were found in CDH1 or LOXL2 expression; however, 
a significant reduction in VIM levels were observed 
after MAD2L1 interference (Figure 4A). At the level of 
the percentage of cells expressing CSC surface 
markers, we observed a significant reduction in the 
percentage of CXCR4, CD90 and CD133-positive cells. 
Autofluorescence was not assessed as shM cells 
express GFP, making it impossible to assess auto-
fluorescence (Figure 4B). 
Since the aforementioned data indicated a 
potential decrease in the CSC population, we next 
assessed CSC functional properties (ALDH1 activity 
and self-renewal). To our surprise, ALDH1 activity 
remained high in MKN45, showing almost 2-times 
more activity in shM versus WT MKN45CSCs (Figure 
4C). Likewise, SFE for WT was approximately 21.35% 
while for shM a SFE of around 39.58% was calculated 
(Figure 4D). 
It is important to note that although MAD2L1 
silencing in MKN45 cells was significantly reduced, 
silencing was not > 50%. Additional silencing 
attempts to further reduce MAD2 levels were 
unsuccessful (data not shown), which we attribute to 
lethal effect in MKN45 cells, as these cells expressed 
the lowest levels of MAD2 across the three GC cells 
lines initially tested. Therefore, MAD2L1 was silenced 
in SNU638 cells, which expressed the highest levels of 
MAD2 (Figure 3A), and we achieved a greater than 
50% reduction in MAD2L1 (Figure 4E). Interestingly, 
with a more robust reduction in MAD2, we observed 
in shM SNU638CSCs a significant inhibition in ALDH1 
activity (Figure 4E) and a reduction in SFE (Figure 4F), 
indicating that the levels of MAD2 are key to impact 
GCSC properties. To test this hypothesis in 
MKN45CSCs, we decided to abolish the activity of 
MAD2 by using the inhibitor M2i-1 in MKN45CSCs in 
lieu of silencing MAD2L1. Following M2i-1 treatment, 
we analyzed sphere formation capacity via a limiting 
dilution assay and index sorting. Our results showed 
that the activity of MAD2 is essential for CSC 
phenotypes, and only when MAD2 levels are reduced 
to suboptimal levels or its activity is completely 
inhibited do GCSC lose their inherent stem-associated 
phenotypes (Figure 4G). 
Next, as chemoresistance is another hallmark 
trait of CSCs, we asked whether sensitivity to 
standard chemotherapeutics was affected as a 
consequence of modulating MAD2 levels in 
MKN45CSCs and SNU638CSCs. We tested cell survival 
using an MTS assay, 72 h after the treatment with 
increasing amounts of bleomycin (0-10 µg/mL), 
paclitaxel (0-0.5 µM) and cisplatin (0-10 µg/mL). As 
expected, GCSCs were more resistant to the indicated 
treatment compared to adherent cells. Interestingly, 
reduced levels of MAD2 did not have any significant 
effect on survival regardless of the level of MAD2L1 
silencing (Figure 5). 
Altogether, the above results suggest that MAD2 
levels have an impact on the stemness phenotype in 
GCSCs, but not in the therapy response, and a certain 
threshold of MAD2 levels and/or activity is required 
for the GCSC state. 
MAD2 modulates migration, invasion and in 
vivo tumorigenesis 
Having observed a reduction in VIM in shM 
MKN45CSCs, we performed in vitro assays to analyze 
migration and invasion under conditions of MAD2L1 
downregulation. Our results showed that depleting 
MAD2 reduces both the median migration and 
invasion in a transwell assay (43.75 to 26 cells/field 
and 89 vs 23.5 cells/field, respectively) (Figure 6A). 
Identical results were also observed for shM 
SNU638CSCs, indicating that maximum MAD2 
silencing is not necessary to affect migration and 
invasion (Figure S4). 






Figure 4. MAD2 modulates pluripotency and stemness ability in GC cell lines. (A) The interference of MAD2L1 in MKN45CSCs (shM) was confirmed by RT-qPCR. The 
relative expression levels of NANOG, SOX2, OCT3/4, LGR5, CDH1, VIM and LOXL2 mRNAs were quantified by RT-qPCR in the MKN45CSCs. Each gene was normalized to GAPDH. 
Fold changes were calculated relative to the non-interfered CSCs (WT). At least, three independent experiments were performed with similar results. (B) Flow cytometric 
analysis of CXCR4, CD90 and CD133 cell surface markers in MKN45CSCs after interference of MAD2L1. The histograms summarize the percentage of CXCR4-, CD90- and 
CD133-positive cells in sphere cultures from three different experiments. Fold changes were calculated compared to WT. Representative plots with the percent-positive cells 
present within the single-cell, live and debris-free population are shown. (C) ALDH activity profile. MKN45CSCs after interference of MAD2L1 were counter-stained with AldeRed 
to determine the frequency of ALDH-positive cells by flow cytometry, in the presence or absence of the ALDH inhibitor (DEAB). ALDH activity is expressed as mean of the 
percentage of positive cells of 3 experiments. Representative plots are shown, in the presence or absence of the ALDH inhibitor (DEAB), with the percent-positive cells present 
within the single-cell, live and debris-free population. (D) Secondary sphere formation efficiency in MKN45CSCs with reduced MAD2 levels. 1 cell/well was seeded by sorting and 
spheres were counted 10 days later. Graphs show the percentage of the total number of spheres formed/total number of cells seeded (SFE: sphere formation efficiency). Right 
panels show representative images of tumorspheres. Scale bar: 100 µm. (E) RT-qPCR for MAD2L1 and ALDH activity profile in SNU638CSCs. mRNA levels of MAD2L1 and 
frequency of ALDH-positive cells were quantified as in (A) and (C), respectively. (F) Secondary sphere formation assay in SNU638CSCs with reduced MAD2 levels. 250 cells/well 
were seeded and SFE was calculated as in (D). Panels below show representative pictures of tumorspheres. Scale bar: 100 µm. (G) Secondary sphere-forming capacity of 
MKN45CSCs in presence of the MAD2 inhibitor, M2i-1 (25 µM), after ten days, 1 cell/well in left panel (by sorting) and 5 cells/well in right panel. Graphs show the percentage of 
the total number of spheres formed/total number of cells seeded. Right panels show representative images of tumorspheres when seeding 5 cells/well. Scale bar: 100 µm. The 
experiments (D, E, F, G), were repeated three times with similar results. Statistical significance was evaluated with two-tailed Student's t-test (*P < 0.05; **P < 0.01; ***P < 0.001). 






Figure 5. Chemoresistance in GCSCs. Cell viability was quantified using MTS assay after 72 h of bleomycin (BLM), paclitaxel (PXL) and cisplatin (CDDP) treatment in 
increasing concentrations in MKN45 and SNU638 cell lines cultured in adherence (ADH) or as sphere (CSCs), after MAD2 downregulation (CSCs shM) or not (CSCs WT). 
Results are presented as the percentage of viable cells relative to untreated cells. Data represent the mean values obtained in three experiments performed in quadruplicate. The 
statistical significance was evaluated with one-way ANOVA, followed by post hoc comparisons (Bonferroni´s test, *P < 0.05; **P < 0.01; ***P < 0.001). 
 
Since matrix MMPs are crucial for the 
progression of the invasion process, we analyzed the 
expression in MKN45CSCs of some of the more 
common MMPs implicated in invasion ability: MMP9, 
MMP2 and MMP1. Our results showed that in shM 
MKN45CSCs the mRNA levels for those MMPs 
dropped to less than half the values of those 
measured in WT MKN45CSCs (Figure 6B). We also 
studied the activity of MMPs in conditional medium 
from MKN45CSCs by zymography assay, and observed 
that MMP1 and MMP2 activity were reduced under 
MAD2 downregulation (Figure 6B). Finally, analyzing 
mRNA levels for known EMT genes we corroborated 
that key transcription factors involved in the EMT 
process (i.e. SNAI1, SNAI2, ZEB1 and TWIST) are 
downregulated after MAD2L1 interference (Figure 
6C). 
Finally, a xenograft assay was performed in 
immunocompromised mice to evaluate the role of 
MAD2 in tumor take and progression. MKN45 WT 
and MKN45 shM cells were subcutaneously injected 
in both flanks of immunocompromised mice (n=8). 
Tumor incidence was unchanged regardless of MAD2 
levels (8/8), however the tumors continuously 
increased in size in the WT; while in shM tumor 
growth was significantly delayed. We also tested the 
potential effect of M2i-1 on tumor growth, by 
pre-treating WT cells prior to injection. We observed 
that tumor volume was intermediate between WT and 
shM cells, probably due to a reversible effect of the 
inhibitor. Tumor weight correlated with tumor 
volume, with an average of 220 mg for WT cells vs 
~100 mg for those tumors where activity or expression 
of MAD2 was inhibited (Figure 7A). H&E staining 
showed large necrotic areas in those tumors with 
MAD2 activity modulated compared with WT, and 
quantification of the viable tumor surface indicated a 
reduction of approximately 40% when MAD2 was 
targeted (Figure 7B). 
Upon termination of the experiment, we 
performed ex vivo analyses of the resected tumor to 
assess specific parameters. First, we verified that 
sh-mediated interference was maintained along the 
course of the experiment by RT-qPCR analysis of 
MAD2L1. We then analyzed the levels of MMPs 
between tumors and observed that MMP1 was 
reduced in the shM group, while there was no 
significant modification in MMP2 or MMP9 (Figure 
7C). Analysis of SNAI1, SNAI2, ZEB1 and TWIST 
showed a decreasing trend in shM, with only SNAI2 
reaching significance (Figure 7D). Previous works 
showed that one of the consequences of MAD2 
reduction is induction of senescence [13]. Therefore, 
we tested molecular markers for senescence (IL6, IL8 
and p21), and we only found a moderate increase in 
IL8 expression (Figure 7E). In addition, p53 activation 
was not observed under the conditions of our study 
(data not shown). Altogether, our results indicate that 
MAD2 levels control migration/invasion and tumor 
growth in vitro and in vivo, respectively, through the 





reduction of MMPs and transcription factors involved 
in EMT and stemness. Furthermore, this delay in 
growth appears not to be related with senescence. 
 
 
Figure 6. MAD2 levels regulate migration and invasion in MKN45CSCs. (A) Transwell migration (top) and invasion (bottom) assay in MKN45CSCs after MAD2 
downregulation. Graphs show the quantification of stained migratory and invasive cells, respectively, from CSCs WT and shM using the transwell assay, without and with 20% 
serum-free conditioned medium from M2-differentiated human macrophages (CM) at 48 h. Representative photographs of the experiment are shown on the right. Scale bar: 100 
µm. (B) Analysis of MMPs in MKN45CSCs with reduced MAD2 levels. The relative expression levels of MMP9, MMP2 and MMP1 mRNAs were quantified by RT-qPCR. Each gene 
was normalized with GAPDH. Fold changes were calculated compared to WT. On the right, gelatin zymography assay of MMP9, MMP2 and MMP1 activities. (C) RT-qPCR analysis 
for EMT genes SNAI1, SNAI2, ZEB1 and TWIST as in (B). At least, three independent experiments were performed with similar results. The statistical significance was evaluated 
with one-way ANOVA, post hoc comparisons, Bonferroni´s test, or two-tailed Student's t-test (*P < 0.05; **P < 0.01; ***P < 0.001). 






Figure 7. MAD2 downregulation reduces tumorigenesis in vivo in MKN45 cell line. (A) MKN45 cells (WT), after MAD2L1 downregulation (shM) and in presence of 
the MAD2 inhibitor M2i-1 (M2i-1), were subcutaneously injected (5 × 103 cells), into the flanks of nude mice. Growth of tumors was monitored by measurement of tumor size 
at specific time points. Tumors were dissected and weighed at the end of the experiment and results are represented in the middle panel. Representative images from the tumors 
are shown in the upper right panel. (B) Hematoxylin-eosin staining in tumor sections from MKN45 WT, M2i-1 and shM tumors with viable areas traced (Magnification 2x, Scale 
bar: 500 µm). Detail of tumor tissue with necrotic areas are traced (Magnification 10x. Scale bar: 100 µm). On the left, graph showing the viability of the tumors relative to 
wild-type cells-tumors (WT). Data represent the mean values obtained from three sections per tumor cut by the maximum diameter to be representative. (C-E) RT-qPCR 
analysis for MAD2L1 and MMP9, MMP2 and MMP1 (C), EMT genes SNAI1, SNAI2, ZEB1 and TWIST (D) and senescence-related genes IL-6, IL-8 and p21 (E) in tumors resected 
for the experiment in (A). Each gene was normalized to GAPDH. Fold changes were calculated compared to WT. Data represent the mean values obtained from three different 
tumors for each condition. Error bars represent ± SEM. The statistical significance was evaluated with one-way ANOVA, followed by post hoc comparisons (Bonferroni´s test, 
*P < 0.05; **P < 0.01; ***P < 0.001). 






GC is the third leading cause of worldwide 
cancer deaths, trailing lung and colorectal cancer in 
overall mortality. While GC survival rates have 
steadily improved over the past 40 years thanks to 
earlier detection and better treatment options, high 
incidence and mortality contributes to a still dismal 
prognosis [1]. Previous reports have shown that CSCs 
are responsible for cancer recurrence and resistance to 
therapy [6]. Although a significant correlation 
between Chromosome instability (CIN), CSCs and GC 
has attracted much attention from researchers, the 
detailed mechanism by which CIN mediates its effects 
on GC progression remains largely unknown. In the 
present study, we demonstrated for the first time that 
MAD2 levels, a key mitotic checkpoint protein, alters 
the phenotype and behavior of gastrospheres, 
specifically stemness characteristics, EMT, MMPs and 
tumorigenic capacity. 
MAD2 overexpression promotes aneuploidy, 
tumorigenesis and leads to lung tumour relapse in 
mice [24, 25]. In human cancers, high expression of 
MAD2 is also a common feature, with conflicting data 
regarding prognosis [13]. These contradictory data 
come from the fact that the tolerance of CIN is tissue 
specific; thus, the absence of MAD2 is incompatible 
with embryonic development [26] and toxic to hair 
follicle stem cells [27], but tolerated by basal epidermal 
cells [27], T cells and hepatocytes [28]. We propose 
here that there is a threshold of MAD2 levels in the 
tumor and in GCSCs, and levels that fall below the 
“minimum” will affect GCSCs stemness 
characteristics, minimizing their self-renewal and 
tumorigenic potential. GCSCs express MAD2, 
although to levels less than that observed in their 
non-CSC adherent counterparts. Thus, CSCs need "a 
certain level MAD2 protein" for specific stem-related 
functions (i.e. self-renewal). We hypothesize that this 
threshold varies across cell lines. For example, 
MKN45 cells are less tolerable to low, prolonged and 
potent genetic silencing of MAD2. When levels are too 
low, cells die and only those cells with levels just 
above the critical threshold survive. These surviving 
cells show modulation of several CSC-related 
properties (e.g. stem-associated gene and cell surface 
maker expression, migration, invasion and tumor 
growth) but others are only marginally inhibited (e.g. 
self-renewal). Other cells, such as SNU638, better 
tolerate MAD2 inhibition. SNU638 cells showed more 
efficient MAD2 interference compared to MKN45 
cells. In these cells, SFE formation was significantly 
inhibited. Finally, it is important to note that using a 
MAD2 pharmacological inhibitor in lieu of shRNA- 
mediated MAD2 silencing; we show that MAD2 
activity is required for SFE formation in MKN45 cells. 
In addition, we hypothesize that MAD2 levels 
influence the balance between symmetric and 
asymmetric division during mitosis [29]. For instance, 
in the hematopoietic system, a decrease in MAD2 
levels favour asymmetric rather than symmetric cell 
division and therefore an increase in the number of 
progenitors that subsequently will differentiate into 
the corresponding cell types [10]. Moreover, MAD2 
mutants in flies with abnormal number of 
centrosomes shows defects in spindle position and 
tumor reduction associated with asymmetric division 
and differentiation due to a decrease in the number of 
proliferative adult intestinal stem cells (ISC), which 
leads to premature differentiation [30]. MKN45 CSCs 
show multipolar mitosis, thus, we can hypothesize 
that addition of aneuploidy to a tumour-permissive 
background would influence the tumorigenic 
capacity. 
Our data highlights that decreasing MAD2 in GC 
may favour a heterogenic CSC population, with a 
mixed phenotype of more differentiated cells with 
lower expression of EMT and stemness genes. 
Heterogenic CSC populations are common and have 
been observed in other tumor entities, such as breast 
cancer where a mix of E/M hybrid CSCs has been 
observed, correlating to higher stemness and worse 
overall survival [18]. These mixed heterogenic states 
are difficult to define as specific markers for specific 
CSCs or CSC states do no exists, and even though a 
wide array of potential markers have been described 
in the literature, it is nearly impossible to associate 
some stemness genes with specific prognostic markers 
for GC. Our results show that no changes were found 
in E-cadherin and Vimentin between ADH and CSCs, 
which may be due to the fact that cancer cells are able 
to switch between different phenotypic states. 
However, low MAD2 gastrospheres from MKN45 
exhibit a decrease in EMT-transcription factors such 
as VIM and SNAI2 and many stemness genes and 
CSC-associated cell surface markers, indicating a shift 
in the GCSC population as a whole, shifting the 
balance from GCSC with high tumorigenic capacity 
(e.g. tumor-initiating GC stem-like cell) to GCSCs with 
low tumorigenic capacity [31]. 
CXCR4 is a G-protein-coupled receptor for 
stromal-derived-factor-1 (SDF-1) which, in its 
activated state, is able to modulate signalling 
pathways that in turn activate the expression of genes 
including some MMPs involved in metastasis [2]. 
Therefore, inhibition of CXCR4 in osteosarcoma 
decreases invasion and MMP1 expression [32]. 
Related to this, our data shows the same correlation in 
cells in vitro, low MAD2 in MKN45CSCs decreases 
CXCR4 expression and MMP1 expression and 
activity, which correlates with a reduction in their 





migratory and invasive capacity in vitro. In addition, 
downregulation of MAD2 in MKN45 cells 
significantly reduces the growth of xenografts in 
immunocompromised mice, concomitant with a 
decrease in MMP1 and SNAI2. Based on this, we 
hypothesize, what is known in breast cancer [33], that 
SNAI2 controls MMP1 expression in GCSCs. In 
agreement with our in vivo results, it is known that 
MAD2 levels modulate the ratio of hematopoietic stem 
cells/progenitors to engraft, repopulate and serially 
transplant into recipient mice [10]. We believe that the 
experiments presented herein strongly suggest that 
MAD2 could be implicated in the metastasis processes 
of GC, as 1) it is overexpressed in most adeno-
carcinomas, and 2) MAD2 inhibition compromised 
the viability of GCSCs both in vitro and in vivo. 
The M2i-1 inhibitor has been shown to disrupt 
the assembly of the mitotic checkpoint complex 
(MCC) [34, 35]. Our results show that GCSC in vitro 
viability and self-renewal are significantly impacted 
in presence of M2i-1, and in the in vivo experiments, 
intermediate tumor growth kinetics and growth are 
observed. The less potent effect in vivo is likely due to 
the fact that the pharmacological effect is lost or the 
doses for treatment in vivo are not as effective as in 
vitro. Further research is needed in order to find new 
molecules that target MAD2 and to clarify the strong 
effect of this protein over GCSCs. Recent studies 
indicate that combined treatment with Taxol and 
M2i-1 increases HeLa cell death, by promoting 
apoptosis [36]. Furthermore, MAD2 siRNA (siMAD2)- 
loaded on nanoparticles, has been presented as an 
attractive drug delivery platform for RNAi 
therapeutics against NSCLC [37]. It would be 
interesting to verify if the incidence of GC tumors 
could also be reduced with similar MAD2-targetting 
therapeutic approaches and combinations. 
One of our results which clearly need to be 
thoroughly investigated in the near future is the 
influence of MAD2 levels on transcriptional 
regulation. We have clearly shown that when MAD2 
is depleted the transcriptional program of GCSCs 
changes; however, the effect was variable across GC 
cell lines. One explanation could be a change in the 
transcriptome during the process of differentiation of 
GCSCs and EMT, which could influence not only the 
expression of certain transcription factors and 
therefore the induction of repressed genes, but also 
microRNA expression [38]. Another possibility is that 
since MAD2 is a flexible protein thanks to its HORMA 
domain, its modulation can have radically different 
functional outcomes beyond just mitosis, as has been 
recently described and may explain some of our 
findings [39]. The module p31Commet-MAD2-BUBR1 
binds the insulin receptor linking mitotic proteins to 
nutrient metabolism [40]. Wilms' tumor-1 protein 
(WT1) is a transcription factor that can either activate 
or repress genes to regulate cell growth, apoptosis 
and differentiation, and it is also able to interact with 
MAD2 and modulate mitosis control [41]. Finally, a 
MAD2-mediated translational regulatory mechanism 
promoter S-phase cyclin synthesis has been described 
in yeast [42]. We should like to finish off with one last 
consideration regarding the MAD2 function outside 
mitosis in stem cells. The normal state for these cells is 
quiescence, in which cells are outside cell cycle, so the 
high levels of MAD2 suggest new biological functions 
to study. 
Finally, considering the aforementioned role of 
MAD2 in tumorigenesis, we hypothesize that GCSCs 
from tumors with high levels of MAD2 have an 
activated CXCR4-SNAI2 signalling pathway, 
increasing the expression of MMP1, which translates 
into higher invasion and tumor growth. Targeting 
MAD2 could downregulate this pathway, promoting 
asymmetric division and lowering metastasis 
(Figure 8). Without a doubt, the role of MAD2 appears 
to extend beyond that of merely modulating mitosis, 
and its utility in the search for new therapeutic 
avenues to control cancer and CSCs should be fully 
exploited. 
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Figure 8. Working model of how MAD2 downregulation promotes asymmetric division and reduces tumor growth and invasion in MKN45 cell line. CSCs 
with high levels of MAD2 (left) enhances symmetric division and increases tumor growth by activating the signaling pathway CXCR4-SNAI2-MMP1. Targeting MAD2, with 
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